Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 7/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16797513 | 0.87 | SMN1; SMN2 (0.36) | GAAMEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL19031895 | 0.84 | CNR2 (0.38) | GAAMEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL17318002 | 0.84 | SMN1; SMN2 (0.36) | GAAMEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL17768392 | 0.81 | KDM4E (0.37) | GAAMEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL17318012 | 0.81 | KMT2A (0.34) | GAAMEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL18982196 | 0.80 | CYP4F2 (0.43) | GAAMEN1KMT2ASMN1; SMN2SYK | |
| SCHEMBL17583206 | 0.78 | POLB (0.37) | GAASMN1; SMN2SYKKDM4EPOLB | |
| SCHEMBL19616595 | 0.74 | CNR2 (0.39) | MEN1KMT2ATSHRCNR2POLB | |
| SCHEMBL17765157 | 0.73 | POLB (0.41) | GAAMEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL18982891 | 0.72 | CNR2 (0.38) | GAAMEN1KMT2ASMN1; SMN2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10925876-B2 | Methods for using triazolo-pyrazinyl soluble guanylate cyclase activators in fibrotic disorders | MERCK SHARP & DOHME CORP. (US) | 2021-02-23 | — | — | US | disclosed |
| US-10925876-B2 | Methods for using triazolo-pyrazinyl soluble guanylate cyclase activators in fibrotic disorders | MERCK SHARP & DOHME CORP. (US) | 2021-02-23 | — | — | US | disclosed |
| EP-3221319-B1 | TRIAZOLO-PYRAZINYL DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME (US) | 2019-10-30 | — | — | EP | disclosed |
| EP-3221319-B1 | TRIAZOLO-PYRAZINYL DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME (US) | 2019-10-30 | — | — | EP | disclosed |
| US-20190282579-A1 | METHODS FOR USING TRIAZOLO-PYRAZINYL SOLUBLE GUANYLATE CYCLASE ACTIVATORS IN FIBROTIC DISORDERS | MERCK SHARP & DOHME CORP. (US) | 2019-09-19 | — | — | US | disclosed |
| US-20190282579-A1 | METHODS FOR USING TRIAZOLO-PYRAZINYL SOLUBLE GUANYLATE CYCLASE ACTIVATORS IN FIBROTIC DISORDERS | MERCK SHARP & DOHME CORP. (US) | 2019-09-19 | — | — | US | disclosed |
| EP-3458063-A1 | METHODS FOR USING TRIAZOLO-PYRAZINYL SOLUBLE GUANYLATE CYCLASE ACTIVATORS IN FIBROTIC DISORDERS | Merck Sharp & Dohme Corp. (US) | 2019-03-27 | — | — | EP | disclosed |
| WO-2017200857-A1 | METHODS FOR USING TRIAZOLO-PYRAZINYL SOLUBLE GUANYLATE CYCLASE ACTIVATORS IN FIBROTIC DISORDERS | MERCK SHARP & DOHME CORP. (US) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017200857-A1 | METHODS FOR USING TRIAZOLO-PYRAZINYL SOLUBLE GUANYLATE CYCLASE ACTIVATORS IN FIBROTIC DISORDERS | MERCK SHARP & DOHME CORP. (US) | 2017-11-23 | — | — | WO | disclosed |
| US-9822130-B2 | Triazolo-pyrazinyl derivatives useful as soluble guanylate cyclase activators | MERCK SHARP & DOHME CORP. (US) | 2017-11-21 | — | — | US | disclosed |
| US-9822130-B2 | Triazolo-pyrazinyl derivatives useful as soluble guanylate cyclase activators | MERCK SHARP & DOHME CORP. (US) | 2017-11-21 | — | — | US | disclosed |
| EP-3221319-A1 | TRIAZOLO-PYRAZINYL DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | Merck Sharp & Dohme Corp. (US) | 2017-09-27 | — | — | EP | disclosed |
| US-20170073355-A2 | TRIAZOLO-PYRAZINYL DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. (US) | 2017-03-16 | — | — | US | disclosed |
| US-20170073355-A2 | TRIAZOLO-PYRAZINYL DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. (US) | 2017-03-16 | — | — | US | disclosed |
| US-20160145272-A1 | TRIAZOLO-PYRAZINYL DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. (US) | 2016-05-26 | — | — | US | disclosed |
| US-20160145272-A1 | TRIAZOLO-PYRAZINYL DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. (US) | 2016-05-26 | — | — | US | disclosed |
| WO-2016081668-A1 | TRIAZOLO-PYRAZINYL DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. (US) | 2016-05-26 | — | — | WO | disclosed |
| WO-2016081668-A1 | TRIAZOLO-PYRAZINYL DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. (US) | 2016-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170073355-A2 | TRIAZOLO-PYRAZINYL DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | PDE3A, PDE2A, PDE3B | GAA 210/4885MEN1 2292/4885KMT2A 4660/4885 |
| US-20160145272-A1 | TRIAZOLO-PYRAZINYL DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | PDE3A, PDE2A, PDE3B | GAA 210/4885MEN1 2292/4885KMT2A 4660/4885 |
| US-20190282579-A1 | METHODS FOR USING TRIAZOLO-PYRAZINYL SOLUBLE GUANYLATE CYCLASE ACTIVATORS IN FIBROTIC DISORDERS | GUCY1B1, GUCY1A1, GUCY1A2 | GAA 1529/4885MEN1 2799/4885KMT2A 4085/4885 |
| US-10925876-B2 | Methods for using triazolo-pyrazinyl soluble guanylate cyclase activators in fibrotic disorders | GUCY1B1, GUCY1A1, GUCY1A2 | GAA 1529/4885MEN1 2799/4885KMT2A 4085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.